Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systematic profiling of staralog response to acquired drug resistant kinase gatekeeper mutations in targeted cancer therapy.

Amino acids - 1 Apr 2020

Yang Yuping, Qiu Yue, Liu Xu, Liu Yanhua, Yin Yaling, Li Peng

Abstract excerpt

Kinase-targeted therapy has been widely used as a lifesaving strategy for cancer patients. However, many patients treated with targeted cancer drugs are clinically observed to rapidly develop acquired resistance. Kinase gatekeeper mutation is one of the most chief factors contributing to the resistance, which modulates the accessibility of kinase's ATP-binding pocket. Previously, the pan-kinase inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Molecular Targeted Therapy

Share to Protein Conformation

Share to Protein Kinase Inhibitors

Share to Staurosporine

Source

Identifiers

PMID: 32206932
DOI: 10.1007/s00726-020-02832-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systematic profiling of staralog response to acquired drug resistant kinase gatekeeper mutations in targeted cancer therapy.PMID 32206932Read ↗

Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations.Semantic proximity Read ↗

Targeting Gatekeeper Mutations for Kinase Drug DiscoverySemantic proximity Read ↗

Integrated Exploitation of the Structural Diversity Space of Chemotherapy Drugs to Selectively Inhibit HER2 T798M Mutant in Lung Cancer.Semantic proximity Read ↗

Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.Semantic proximity Read ↗

Systematic profiling of chemotherapeutic drug response to EGFR gatekeeper mutation in non-small cell lung cancer.Semantic proximity Read ↗

The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.Semantic proximity Read ↗

Advances in protein kinase drug discovery through targeting gatekeeper mutations.Semantic proximity Read ↗

Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.Semantic proximity Read ↗

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.Semantic proximity Read ↗

Landscape of drug-resistance mutations in kinase regulatory hotspotsSemantic proximity Read ↗

An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.Semantic proximity Read ↗

Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.